A survey conducted by YouGov has found that a majority of U.S. citizens have used marijuana before, and most of them revealed that the experience was a positive one. This survey also discovered that 20% of Americans have also tried “magic mushrooms” (psilocybin mushrooms), and an even bigger proportion of these users reported that the experience was a positive one.
This poll comes at a time when the Biden administration is taking steps to reschedule marijuana while many states are also looking to reform their laws around psychedelics. The poll provides a deep dive into what Americans think of these efforts to tweak the different policies and laws on these substances.
The poll asked respondents about four substances: cannabis, LSD, psilocybin and MDMA. Marijuana led with a wide margin (57%) when respondents were asked to indicate the substances they had ever used, psilocybin came in second at 20%, LSD followed at 16%, and MDMA rounded off the set at 11%.
The respondents who admitted using any of those substances also reported that their experience was a positive one. The survey noted that 65% of psilocybin mushroom users categorized their experience of the substance as positive, 57% said using marijuana was a positive experience, 56% said the same for MDMA while 55% had a positive experience using LSD. Psilocybin stands out as having the largest percentage of its users describing the experience as positive.
It is noteworthy that only 8% of those who admitted using psilocybin described it as a negative experience while 20% said using LSD, marijuana or MDMA was a negative experience.
On matters of legalization, cannabis stood out by attracting majority support with 60% saying its use should be made legal. Only 27% wanted psilocybin legalized, 16% supported MDMA legalization, while 15% said LSD should be made legal.
When the poll narrowed down the legalization question to those who had ever used each of those substances, only LSD didn’t attract majority support for its legalization. Cannabis had 78% of those who had used it saying it should be made legal, 63% of those who had used psilocybin supported its legalization, and 55% of those who had used MDMA said it should be made legal. LSD users were divided on the subject, with 43% voicing their opposition to its legalization while 38% were in support of its legalization.
This survey was conducted April 25–28, 2024. The total number of respondents was 1,134, and only adults were polled. A 4% margin of error was factored into the findings.
The public sentiment toward many psychedelics is likely to spur on startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) to ramp up their R&D drug-development efforts since the public is already positive toward several psychedelic compounds.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”)
Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated
Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control
Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced a partnership with the National Research Council of Canada (“NRC”) that will pursue an applied research program to evaluate specific molecular characteristics of the company’s patented DehydraTECH(TM) technology processed with glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance (https://cnw.fm/tFjNC).
The work program will utilize simulated gastric fluid, mimicking conditions in the human gut. In addition, various testing methods will be employed, among them size exclusion chromatography (“SEC”), polyacrylamide gel electrophoresis (“PAGE”), dynamic light scattering (“DLS”), and matrix-assisted laser desorption ionization mass spectrometry (“MALDI MS”).
GLP-1 drugs have shown significant benefits in weight management and addressing diabetes. Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood than an unprocessed Rybelsus(R) tablet. The benefits also extend to doing away with painful injections, which are the norm with GLP-1 delivery.
Lexaria’s management believes this partnership could help fast-track the company’s push for the adoption of DehydraTECH with GLP-1 drugs. It will also be integral in showcasing the potential of the technology while inching the company closer to tapping into an industry projected to be valued at $133.5 billion by 2030 (https://cnw.fm/GjFj1).
“We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid introduction possible of DehydraTECH with GLP-1 drugs,” noted John Docherty, Lexaria’s president.
This partnership follows Lexaria’s resolve to double down on GLP-1 studies for the 2024 calendar year. It also follows the recent independent third-party ethics review board approval for its GLP-1 human pilot study #2, which seeks to explore the oral delivery of GLP-1 drugs. In addition, in March Lexaria announced details of its WEIGHT-A24-1 animal study which will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://cnw.fm/Qdt0X).
Lexaria’s management is confident that by identifying the molecular behavior of DehydraTECH-processed pure semaglutide compositions, the findings will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year. In addition, it is hopeful that this could ultimately lead to alternative formulations with enhanced performance. The program is expected to be completed in early August, with results reported as soon as possible after that.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Yerba Mate, in Spanish, or chimarrão in Brazilian, is a non-alcoholic beverage that in South America has been consumed for centuries and that now is gaining popularity also outside its original land thanks to its beneficial properties on health and its stimulating activity.
Yerba Mate, also known as Paraguayan tea, is obtained from the leaves of the tree Ilex paraguariensis, a member of the South American family of Aquifoliaceae. Guarani people, living around the Paraguay River basin, are reported to be the first consumers of the tea and they considered the plant a gift from Mother Earth.[1] Later on, Jesuits who colonized those lands around 1670 appreciated this beverage’s properties and started to cultivate the tree professionally. When the order was dissolved, the plantations were abandoned and became wild until the 20th century, when the difficult art of cultivating this plant was recovered. [2]
Ilex paraguariensis tree is found in the North of Argentina, which is the first producer of Yerba Mate, Uruguay, Paraguay, and South of Brazil. The production of Yerba Mate is estimated to be 1.4 million tons per year of which only 5% is exported.[2] The plant cultivation is not easy: it has been attempted in other countries with a similar climate with unsuccessful results.[1] Indeed, Ilex paraguariensis can bear temperatures as low as -6 °C but needs high humidity with rain-falls not under 1200 mm.[3]
The beverage commonly called mate, owes its name to its jar. The word “mate” comes from matì, which in Quechua means “herbs from the calabash” because the original vessel was made from calabash fruit.[2] Dry leaves are put in the bottom of the mate, water – hot or cold – is poured on top, and the beverage is assumed through a bombilla, a straw with a filter that avoids the leaves and the powder to pass. Since leaves can be reused multiple times by adding some water, without the need for any stove or special machine, people drink the brew at any moment of the day, even while walking. Indeed, 30% of South America’s population drinks more than 1L of mate per day.[1]
To make Yerba Mate, 6 to 12 month old leaves are harvested, roasted, and dried. Afterward, they must undergo a period of maturation – at least 12 months – that determines the typical flavor of the brew, followed by a last sieving step. Indeed, the leaves/twigs ratio is different in each Yerba Mate variety and contributes to the quality of the beverage.[2]
Chemical Composition
Yerba Mate dry leaves contain around 200 chemical compounds including some that are highly interesting from a pharmaceutical and/or nutraceutical point. Among all substances that can be extracted from Ilex paraguariensis’s leaves some classes of molecules benefit of a larger attention from researchers thanks to their biological activity.
Polyphenols are among the most studied compounds because of their antioxidant activity. They can be found in many widely consumed foods and drinks. Among these, both green tea and mate are well-known for their antioxidant power due to their high polyphenol content (around 50 µg per mg of dry biomass).[2][3]
However, mate composition- regarding polyphenols – differs from both green and black tea, being rich of chlorogenic acid, the dominant compound belonging to this class, and showing no presence of catechins, which are the major responsible for antioxidant activity in tea.[3] Furthermore, polyphenols content in Yerba Mate can vary with plant exposition to the sun. Indeed, it’s been found that raw materials from sunny plantations were the richest in polyphenols.[2] Among important polyphenols present in Ilex paraguariensis there are the flavonoids rutin and quercetin, important for their antimicrobial and antioxidant activity.[1]
Xanthines are a class of purine alkaloids that are present in worldwide consumed foods and beverages in addition to yerba mate, such as coffee, tea, and chocolate. The most famous xanthine is caffeine, to which the majority of these products owe their success thanks to its stimulating effect.
Yerba Mate presents a significant amount of caffeine (1-2% of dry weight) as long as other methylxanthines such as theobromine and theophylline. The caffeine content in a cup of Mate tea is comparable to that contained in a cup of coffee (around 80 mg), however, since it is possible to brew it multiple times, the final intake is much higher.[3] Furthermore, caffeine concentration in the tea is higher with increasing brewing time and temperature.[2]
Saponins are responsible for the typical bitter taste of mate. They are a water-soluble class of molecules, and triterpene saponins, deriving from ursolic and oleanolic acids, can be found in Yerba Mate.[3]
Other significant components of Yerba Mate are linolenic acids and minerals, both important for a balanced and healthy diet. The first ones can represent a source of supplementation of polyunsaturated fatty acids, while minerals are involved in a lot of human metabolic processes. However, inorganic compounds’ content strongly varies with factors such as soil, weather, and raw material processing.[1][3]
Healing Properties
As previously said, mate owes its success largely to its stimulating activity. Caffeine, indeed, not only stimulates the central nervous system (CNS) but also the heart and muscles, having a significant effect on several functions such as alertness, concentration, mental and physical fatigue, feeling of satiety, thermogenesis, and fat oxidation. An excessive consumption of caffeine (0.5 – 1.5 g per day), however, can cause gastrointestinal upset, increasing heart rate, giving the feeling of anxiety and nervousness.
Even though, as previously said, daily assumption of caffeine from mate can be much more than for coffee, regular Yerba Mate consumers admit that the brew gives them energy, without causing that sense of nervousness that is often registered after drinking a cup of coffee.[1][2]
From a pharmacological point of view, mate has been mainly studied for its antioxidant activity, comparable to that of green tea.[3] Both DPPH radical scavenging radicals and catalase activity assays were used to test in vitro Yerba Mate’s antioxidant activity, which is related to its polyphenol content.[2] A good antioxidant power has a crucial effect on cardiovascular diseases.
Many clinical trials have also been carried out, focusing the attention on lipid peroxidation, and, in particular, on low density lipoprotein (LDL), also known as “bad cholesterol” since it has a key role in the onset of atherosclerosis. Consumption of Yerba Mate has also been associated with higher expression of antioxidant genes.[4] Furthermore, there are studies on Yerba Mate modulating perimenopausal oxidative stress and reducing the occurrence of common cardiovascular diseases in post-menopausal women.[2]
Mate has also shown antidiabetic properties due to the combination of antioxidant and antiglycation effects. It has been proven that the consumption of Yerba Mate has a positive effect on serum lipid parameters in normolipidemic, dyslipidemic, prediabetic and type II diabetic subjects. At the same time, mate reduces the production of advanced glycation end products (AGEs).[4]
Finally, mate has been studied for its weight loss potential. Indeed, mate shows high thermogenic power, without influencing heart rate and blood pressure, that is often a limitation in the use of sympathomimetic drugs as anti obesity thermogenic agents.[5] The best effects on weight loss have been reported when the consumption of mate is accompanied with low-intensity physical exercise. Indeed, mate increases the oxidation of fatty acids, which are the fuel for light and moderate exercises, while reducing the oxidation of carbohydrates, that are mainly burnt during high-intensity exercises.[4]
Different Extractions for Different Molecules
Even though mate tea has proven to be beneficial to consumers, home brewing could not be the most efficient way to assume bioactive compounds contained in mate, since their extraction could be partial.[4] To use mate in pharmaceutical preparations, extraction methods have to be optimized. As already discussed, Yerba Mate contains several compounds, which have different physicochemical properties and thus require different extraction techniques.
The main observation about Yerba Mate extraction is that best recovery yields of polyphenols and xanthines have been found using at least 50% of organic (acetone, methanol, or DMF).[3][6] The use of organic solvents, however, could be troublesome for further nutraceutical applications. These results have been obtained both for traditional extraction methods such as maceration and solvent extraction, and for more recent ones such as ultrasound-assisted extraction. This last method, even though allows to obtain high yields of different compounds, is also affected by high extraction time and solvent-to-sample mass ratio.[3]
A promising method to obtain high yields of xanthines is using supercritical . This method not only allows to reach much higher concentrations than with other methods, but it is a “green” extraction method and doesn’t imply any drawbacks for human health.[3]
The coupling of pressurized liquid extraction () and solid-phase extraction (SPE) with an UV-detector has turned out to be a successful way to simultaneously extract and separate compounds from dry leaves. In this case, water solutions with different ratios have been employed. These solvents are considered to be green and harmless, which is positive for nutraceutical applications. Even though this method has shown similar compounds recovery to other methods, a significant difference was reported regarding flavonoids.[7]
The Dark Side of Mate
The last aspect that has to be mentioned about mate is that an increase in cancer occurrence, particularly of the esophagus, has been registered among mate drinkers. However, in these studies, several factors such as smoking or drinking alcohol, besides drinking mate, have been neglected and it’s hard to attribute the whole responsibility to mate. Furthermore, carcinogenicity is probably not a characteristic of mate itself, but of incidental events.[2][3] Indeed, it has been proven that consuming hot beverages increases the probability of developing some cancers, namely, esophageal, oral, bladder, lung, and renal. It is interesting to note that drinking cold mate tea also induces greater stimulation of thermogenesis and fat oxidation than hot tea, thanks to the simultaneous increase of adrenaline (induced by caffeine) and noradrenaline (induced by cold exposure) plasmatic concentration.[5]
In addition, the incidence of such diseases has also been attributed to the ingestion of toxic polycyclic aromatic hydrocarbons (PAHs). These compounds are not proper of Yerba Mate but can accumulate in it due to soil and atmosphere contamination.[2] It is also highly probable that PAHs are produced during mate processing, which traditionally involves drying the leaves over a smoky wood fire. In the end, PAHs can also be assumed through cigarettes, thus representing again a confounding factor.[3]
Apart from this supposed carcinogenicity, that depends on conditions that can be easily controlled and avoided, it is not difficult to understand why the regard that Guarani people addressed to Ilex paraguariensis has survived to date. Yerba Mate has been proven to be beneficial not only when home brewed, but also in nutraceutical preparations to treat chronic diseases such as atherosclerosis, diabetes, and obesity.
References:
(1) Lutomski, P.; Goździewska, M.; Florek-łuszczki, M. Health Properties of Yerba Mate. Annals of Agricultural and Environmental Medicine 2020, 27 (2), 310–313. https://doi.org/10.26444/aaem/119994.
(2) Gawron-Gzella, A.; Chanaj-Kaczmarek, J.; Cielecka-Piontek, J. Yerba Mate—a Long but Current History. Nutrients. MDPI November 1, 2021. https://doi.org/10.3390/nu13113706.
(3) Heck, C. I.; De Mejia, E. G. Yerba Mate Tea (Ilex Paraguariensis): A Comprehensive Review on Chemistry, Health Implications, and Technological Considerations. Journal of Food Science. November 2007. https://doi.org/10.1111/j.1750-3841.2007.00535.x.
(4) Riachi, L. G.; De Maria, C. A. B. Yerba Mate: An Overview of Physiological Effects in Humans. Journal of Functional Foods. Elsevier Ltd November 1, 2017, pp 308–320. https://doi.org/10.1016/j.jff.2017.09.020.
(5) Maufrais, C.; Sarafian, D.; Dulloo, A.; Montani, J. P. Cardiovascular and Metabolic Responses to the Ingestion of Caffeinated Herbal Tea: Drink It Hot or Cold? Front Physiol 2018, 9 (APR). https://doi.org/10.3389/fphys.2018.00315.
(6) Turkmen, N.; Sari, F.; Velioglu, Y. S. Effects of Extraction Solvents on Concentration and Antioxidant Activity of Black and Black Mate Tea Polyphenols Determined by Ferrous Tartrate and Folin-Ciocalteu Methods. Food Chem 2006, 99 (4), 835–841. https://doi.org/10.1016/j.foodchem.2005.08.034.
(7) Souza, M. C.; Silva, L. C.; Chaves, J. O.; Salvador, M. P.; Sanches, V. L.; da Cunha, D. T.; Foster Carneiro, T.; Rostagno, M. A. Simultaneous Extraction and Separation of Compounds from Mate (Ilex Paraguariensis) Leaves by Pressurized Liquid Extraction Coupled with Solid-Phase Extraction and in-Line UV Detection. Food Chemistry: Molecular Sciences 2021, 2. https://doi.org/10.1016/j.fochms.2020.100008.
This post was originally published by our media partner here.
Auxly Cannabis Group Inc. had a great first three months of the year, with record revenue and margin and adjusted EBITDA in Q1 2024 compared to Q1 in previous years.
Despite this, the company still reported a net loss of $26 million for the three months ending March 31, 2024, an increase from a net loss of $10.2 million in the same period of 2023. The company attributes this increase in losses to the deferred tax expense on the conversion of Imperial Debenture into Shares, which was somewhat offset by improved gross profits and lower expenses.
Revenue from sales of cannabis products in Q1 2024 was $38.4 million, up from $37.5 in the same period in the previous year. Excise on those sales was $13.1 million, compared to $13.6 million in Q1 2023.
Auxly’s revenues for 2023 were primarily from dried flower and re-rolls (59% of all sales). The rest of the sales were for cannabis 2.0 products (namely vapes, but also edibles, oils, and topicals). Most of these sales (approximately 76%) were in British Columbia, Alberta, and Ontario.
Gross profit was $9.5 million, compared to $7.9 million in the same period in 2023. Adjusted EBITDA was $2.2 million, compared to just $138,000 in the first three months of 2023.
Wages and benefits declined to $4.3 million for the first quarter of 2024, compared to $4.7 million for the same period of 2023. These decreased expenses were reportedly related to Auxly’s “streamlining of operations and support staff.”
“Following a transformative year for Auxly, we have maintained our positive momentum in the first quarter of 2024 and are continuing to achieve profitable growth,” says Hugo Alves, CEO of Auxly. “Q1 2024 was the best Q1 in Auxly history across key metrics of revenue, gross margin and adjusted EBITDA. Our commitment to product quality, innovation and distribution excellence drove our top-line sales growth year-over-year, and our continued focus on operational efficiency and prudent capital management helped us deliver another quarter of adjusted EBITDA profitability.
“This is all thanks to the collective efforts of our talented and dedicated employees, who work hard every day to make quality products that help our consumers live happier lives. As we head into summer, we are excited to offer consumers new and innovative products to enjoy like our new larger Back Forty 0.75g pre-rolls, which will also be available to consumers in Quebec. We look forward to another quarter of sustainable, profitable growth and, as always, we will remain passionately committed to our consumers.”
Auxly’s brand portfolio includes Parcel, Back Forty, Foray, Dosecann, and Kolab Project. The company has secured listings and sold its cannabis products in all Canadian provinces, the Yukon, and the Northwest Territories. In May 2024, Auxly also launched its first branded product in Quebec, the new Back Forty large format 0.75g three-pack pre-rolls.
The Company also conducts wholesale bulk sales of dried cannabis to different licensed cannabis producers in Canada.
Auxly’s cannabis operations are located in Charlottetown, PEI, as well as Ottawa and Leamington, Ontario. The company does not currently have any active international operations or partnerships.
On March 28, 2024, strategic partner Imperial Brands PLC, which previously invested approximately $123.0 million in Auxly in 2019, completed its planned Imperial Debt Conversion. As such, $121.9 million of the principal amount under the Imperial Debenture was converted at an exercise price of $0.81 for 150,433,450 common shares in the capital of the Company.
In addition, $1.5 million of accrued interest was converted and issued, on a private placement basis, into 90,882,667 common shares in the capital of the Company at a price of $0.017. Imperial and Auxly amended the existing amended and restated investor rights agreement dated July 6, 2021, between the parties to, among other things, remove the existing requirement that Imperial will use the Company as its exclusive cannabis partner.
On February 1, 2024, Auxly also announced that it had signed a definitive agreement to an amendment and extension of Auxly Leamington Credit Facility, led by the Bank of Montreal as administrative agent. That deal includes terms to extend the maturity date by two years until December 31, 2025, with an option for Auxly Leamington to extend the maturity date for an additional year by making a $2.5 million principal repayment by December 31, 2025.
The deal also updates Auxly’s EBITDA and other financial and operational covenants for Auxly Leamington, increased quarterly principal payments throughout the term, with the obligations of Auxly Leamington under the amended and restated credit facility to continue to be supported by a $33 million limited guarantee by Auxly and a pledge by Auxly of all its securities of Auxly Leamington.
The company reports it will have insufficient cash to fund its operations for the next 12 months if its sales and margins do not improve or if its general and administrative expenses increase. Auxly’s “ability to sustain profitability and positive cash flows from operations is subject to material uncertainty that may cast significant doubt upon the Company’s ability to continue as a going concern,” reads the report.
Should they be unable to generate enough cash flow from financing and operating activities, the carrying value of Auxly’s assets could be subject to material adjustments.
This post was originally published by our media partner here.
(Globe Newswire) Vancouver – Rubicon Organics Inc., a licensed producer focused on cultivating and selling organic certified, premium cannabis, is thrilled to unveil its latest innovation – the 1964 Supply Co.™ Full Spectrum Extracts (FSE) Resin 510 Vapes.
The 1964 Supply Co.™ portfolio extension represents a strategic move by Rubicon Organic to tap into the fast-growing Canadian cannabis category, vapes. Our premium vapes are designed with a clear mission: to attract legacy consumers into the legal market by offering superior products that deliver an experience reminiscent of their favorite legacy market offerings.
At the heart of the 1964 Supply Co.™ brand are two classic cultivars, Blue Dream and Comatose, which were carefully selected as the first two vapes offerings due to their sought-after aromas and renowned effects. The Rubicon Organics team has worked hard to ensure that the chosen extraction method would best preserve the natural essence of these cultivars, delivering a true-to-flower experience that will set apart the 1964 Supply Co.™ vapes from our competitors.
Every 1964 Supply Co.™ FSE resin vape will be available in premium 510 hardware that was tested to meet the company’s rigorous quality standards. These vapes will soon be available to consumers in all major provinces, including British Columbia, Alberta, and Ontario.
Advertisement
“By utilizing our own premium flower, we can ensure that every 1964 Supply Co.™ vape maintains the exceptional quality and consistency that our consumers have come to expect from our brand,” says Melanie Ramsey, chief commercial officer.
Beyond meeting the consumers needs for high quality vapes, the launch of the 1964 Supply Co.™ FSE resin 510 vapes represents a significant milestone in Rubicon Organics’ strategic growth plan. It not only expands the company’s product portfolio, but also serves to capture market share in the fast growing premium Canadian cannabis vapes segment. By offering a convenient and high-quality vaping experience, Rubicon Organics aims to recruit new consumers while solidifying its position as a leading player in the Canadian cannabis market.
This post was originally published by our media partner here.
How can you tell when it’s you in charge or something else has life by your ‘short hairs’?
Imagine a lantern held in front of you in the darkness. An arms length away, shedding what light it can in the dungeon of lost turns and foul choices. Now let’s say this lantern is your mind, your sole/soul source of light. And yet, it doesn’t have to be…the lantern is but a perspective built on habit, fuel by desire and created by hands that may not be human…or have your best interest at/in heart.
Please enjoy these two videos I had the pleasure of creating with Nathaniel Gillis…a self-professed ‘Demonologist’.
What keeps you up, late at night, before the sun’s dawn brings fresh new sight?
How does the daze of past thoughts maze move time in front of choice.
Is that your voice between your ears or does the dark manifest more fears?
Cheers Lorenzo
This post was originally published on from Randy Rowe and can viewed here: https://newagora.ca/do-demons-dance-in-your-mind/
This post was originally published by our media partner here.
